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Several of the best-studied sex differences in the mammalian brain
are ascribed to the hormonal control of cell death. This conclusion
is based primarily on correlations between pyknotic cell counts in
development and counts of mature neurons in adulthood; the
molecular mechanisms of hormone-regulated, sexually dimorphic
cell death are unknown. We asked whether Bax, a member of the
Bcl-2 family of proteins that is required for cell death in many
developing neurons, might be essential for sex differences in
neuron number. We compared Bax knockout mice and their WT
siblings, focusing on two regions of the mouse forebrain that show
opposite patterns of sexual differentiation: the principal nucleus of
the bed nucleus of the stria terminalis, in which males have more
neurons than do females, and the anteroventral periventricular
nucleus (AVPV), where females have more neurons overall and
many more dopaminergic neurons than do males. Testosterone, or
its metabolites, is responsible for the sex differences in both nuclei.
A null mutation of the Bax gene completely eliminated sex differ-
ences in overall cell number in both the principal nucleus of the bed
nucleus of the stria terminalis and AVPV. Thus, Bax-dependent cell
death is required for sexual differentiation of cell number, regard-
less of whether testosterone decreases or increases cell death. In
contrast, the sex difference in AVPV dopaminergic cell number, as
measured by tyrosine hydroxylase immunohistochemistry, was
not affected by Bax gene deletion, demonstrating heterogeneity of
mechanisms controlling cell number within a single nucleus.
Cell death is a fundamental process in brain developmentcapable of dictating functional relationships between pop-
ulations of neurons. It is thought to play a particularly important
role in the differentiation of areas involved in sexually dimorphic
functions, as several of the best-known sex differences in the
mammalian nervous system involve differences in neuron num-
ber. For example, male rats have many more neurons than do
females in the sexually dimorphic nucleus of the preoptic area,
the principal nucleus of the bed nucleus of the stria terminalis
(BNSTp), and the spinal nucleus of the bulbocavernosus (1–4).
Conversely, in the anteroventral periventricular nucleus
(AVPV), a nucleus at the rostral extreme of the third ventricle
implicated in the control of gonadotrophin secretion, overall
volume, cell density, and the number of dopaminergic neurons
are greater in females than in males (5–7). These sex differences
can be reversed by manipulating testosterone, or its hormonal
metabolites, during perinatal life. In principle, such sex differ-
ences could be caused by the differential birth, migration,
phenotypic differentiation, andor death of neurons in males
and females. Evidence thus far, however, favors the hormonal
regulation of cell death in each case.
In support, females have more cells displaying the morpho-
logical characteristics of apoptosis than do males in the sexually
dimorphic nucleus of the preoptic area, BNSTp, and spinal
nucleus of the bulbocavernosus during perinatal life (8–10).
Conversely, males have more dying (pyknotic) cells than do
females in the AVPV (11), and these patterns of developmental
cell death are reversed by the same hormonal treatments that
reverse sex differences in adult cell number (7–11). Although this
comprises very convincing circumstantial evidence that cell
death is a major factor in sexual differentiation of cell number,
the mechanisms underlying sexually dimorphic, hormone-
regulated cell death have been virtually unexplored.
Likely players in this process are proteins of the Bcl-2 family,
which are potent regulators of death in many cell types. Some
members of this family (e.g., Bcl-2 and Bcl-xL) inhibit cell death,
whereas other family members (e.g., Bax) promote death (12).
Although the precise mechanisms whereby Bcl-2 family mem-
bers control apoptosis are still not clear, much of the available
evidence supports the so-called ‘‘rheostat model,’’ in which the
balance between death-promoting and death-repressing family
members constitutes a critical checkpoint that determines
whether a cell will execute an apoptotic program (13, 14).
Specifically, a critical level of Bax oligomers at the mitochondrial
membrane activates downstream effector molecules such as the
caspases (see ref. 15 for review); death antagonists, such as Bcl-2
and Bcl-xL, may prevent cell death primarily by preventing the
oligomerization of Bax (16). If this model is correct, then Bax is
a singularly important member of the Bcl-2 family. Indeed, a null
mutation of the Bax gene dramatically reduces or eliminates
developmental cell death in peripheral ganglia, spinal and
brainstem motoneurons, the retina, and some areas of the
cerebellum and hippocampus (17). On the other hand, Bax
deletion does not appear to prevent the death of several other
neuronal subtypes (17–19). Thus, many neural areas depend on
Bax for cell death, and in those cells in which Bax is involved the
requirement is profound. Gonadal steroid hormones can regu-
late the expression of Bax and other Bcl-2 family proteins
(20–25), suggesting a mechanism for sexually dimorphic cell
death. Nonetheless, sexually dimorphic brain areas have not
been examined in Bax knockout mice.
In the present study we evaluated neuron number in the
BNSTp and AVPV of mice lacking the Bax gene. These inter-
connected cell groups exhibit opposite patterns of sexual differ-
entiation in rats (26). Although sex differences in overall neuron
number in the BNSTp have not yet been reported for mice, the
cluster of androgen receptor-expressing neurons is larger in male
mice than in females (27). In AVPV, overall cell density is
greater in female mice than in males (5, 25) and, as in rats, female
mice possess about three times as many dopaminergic neurons
in AVPV as do males (28). We reasoned that if Bax is essential
for cell death in the BNSTp and AVPV, then sex differences in
neuron number might be reduced or eliminated in Bax knockout
mice. We now report that deletion of the Bax gene abolishes sex
differences in overall neuron number in both the BNSTp and
AVPV, but does not affect the sex difference in AVPV dopa-
minergic cell number.
This paper was submitted directly (Track II) to the PNAS office.
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Materials and Methods
Animals. Male and female mice heterozygous for the Bax gene
deletion (Bax) on a C57BL6 background were obtained
from The Jackson Laboratory. These animals were derived from
mice originally produced by Korsmeyer and colleagues (29). WT
(Bax) and knockout (Bax) offspring were identified by
PCR amplification of tail DNA using published primer se-
quences (17). Animals were housed three to four per cage in a
12:12 lightdark cycle and held at 22°C. In adulthood (85 days
of age), the mice were overdosed with chloropent, blood was
collected by cardiac puncture, and animals were perfused in-
tracardially with saline followed by buffered formalin. Brains
were removed from the skull, postfixed in formalin, frozen-
sectioned at 30 m, and stained with thionin. Weight of the
testes, seminal vesicles, and bulbocavernosus muscles, as well as
anogenital distance (the length between the phallus and the
anus), were measured in males after perfusion.
As reported (29), we observed a reduction in testis size in adult
Baxmales (210 26 mg versus 61 2 mg; P 0.005). This
finding could be a concern, given the crucial role of testicular
androgens in sexual differentiation. However, the phenotype
results from the failure of a wave of germinal cell death that takes
place just before puberty (30), i.e., after the perinatal sexual
differentiation period. In addition, the defect appears confined
to germ cells of the seminiferous tubules (29); there is no
evidence that the androgen-producing Leydig cells are affected
by Bax deletion. In confirmation, we found no effect of Bax
deletion on anogenital distance (P  0.7), a sexually dimorphic
measure that is sensitive to perinatal androgens, or on weight of
the seminal vesicles or bulbocavernosus muscles, which are
indirect measures of recent androgen exposure (P 0.7 and P
0.9, respectively; data not shown). Finally, RIAs revealed the
expected main effect of sex on serum testosterone levels (male
female; P  0.02), but no effect of genotype (P  0.9) and no
sex-by-genotype interaction (P 0.9; data not shown). Thus, we
found no suggestion of altered testosterone levels in Bax
males.
Volume of Cell Groups, Neuronal Cell Counts, and Cell Size. All
measurements were made on slides coded to conceal the sex and
genotype of the animals. Nuclear volume measurements and
stereological cell counts were performed by using STEREOINVES-
TIGATOR software (MicroBrightfield, Williston, VT). Outlines of
the BNSTp and AVPV were traced in each section, and volume
was estimated by multiplying summed cross-sectional areas by 30
m (the section thickness before histological processing). The
optical disector method was used for cell counts. This method
provides an unbiased estimate of overall cell number that is not
affected by the size, orientation, or packing density of cells (31).
Counting was ipsilateral within a 20  20-m2 counting frame
that was moved in a random-systematic fashion through each cell
group. Cells were recorded that exhibited the morphological
characteristics of neurons and had clearly visible nucleoli that fell
within the counting frame. Parameters were adjusted so that
counts were made in 100–200 locations within each nucleus.
For the BNSTp, alternate sections were sampled, and the spacing
between counting frames was 10,000 m2 (i.e., a sampling grid
of 100  100 m2). For the much smaller AVPV, every section
was counted and a 60  60-m2 sampling grid was used. Upper
and lower guard heights of 1 m were used for each nucleus, to
avoid edge artifacts or the counting of split cells. Mean cell size
in each nucleus was determined by tracing the outlines of at least
50 neurons within the BNSTp and 25 neurons in AVPV of each
animal. Cells for tracing were chosen by randomly placing a grid
over three sections through each nucleus. The sections were
selected to span the rostrocaudal extent of each nucleus and all
cells that fell within a specified area of the grid were traced to
avoid bias in cell selection.
Tyrosine Hydroxylase (TH) Immunohistochemistry. To determine
whether Bax gene deletion influences the number of dopami-
nergic neurons in AVPV, we performed immunohistochemistry
for TH in brains harvested from a separate cohort of mice.
Animals were perfused with 4% paraformaldehyde in borate
buffer, pH 9.5, and 20-m coronal sections were cut into three
series on a freezing microtome. One series of free-floating
sections was double-stained for TH and estrogen receptor 
(ER) (as in ref. 28) by using mouse anti-TH antiserum (1:1,000;
DiaSorin, Stillwater MN) and rabbit anti-ER (1:40,000, Up-
state, Waltham, MA). Secondary antibodies were goat anti-
mouse Alexa 488 and Alexa 568 (both at 1:200; Molecular
Probes) for TH and ER, respectively. ER-immunoreactive cells
were used to select sections containing AVPV and identify the
borders of the AVPV in each animal. TH-immunoreactive
(TH-ir) cells with clearly visible nuclei were then counted in all
sections containing the AVPV.
Data Analysis. The effects of Bax gene deletion on overall cell
number, TH-ir cell number, nuclear volume, and cell size were
evaluated by two-way ANOVAs (sex-by-genotype). Planned
comparisons were performed by using a Fisher’s test if signifi-
cant main effects or interactions were found. Cell counts in
AVPV did not pass a homogeneity of variance test (Bartlett-Box
test, P  0.015), because of greater variances in Bax knockouts
than in WT animals. Data for this dependent variable were
therefore analyzed in two ways: two-way ANOVA followed by
planned comparisons using separate variances (Systat, Evanston,
IL) and the Kruskal-Wallis nonparametric test. Both analyses
gave the identical pattern of outcomes; probabilities from the
ANOVA are reported here.
Results
BNSTp. Subdivisions of the BNST have been given various names
by different investigators. We followed the conventions of Dong
and Swanson (32) in defining the ‘‘principal nucleus’’ (also
known as the ‘‘encapsulated’’ region of the BNST, or the medial
part of the posteromedial subdivision of the BNST; Fig. 1).
Deletion of the Bax gene eliminated a sex difference in BNSTp
cell number (Fig. 2). WT males had 45% more cells in the
BNSTp than did WT females, with no overlap between the sexes
(P  0.001). Bax deletion increased cell number in both sexes,
but more in females than in males, which abolished the sex
Fig. 1. Photomicrograph of the BNSTp (arrows) in a male Baxmouse. LV,
lateral ventricle; 3V, third ventricle. (Scale bar  200 m.)
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difference in cell number in Bax animals (P  0.8). Statis-
tically, these findings were reflected in a main effect of sex (P 
0.01), a main effect of genotype (P  0.0001), and a sex-by-
genotype interaction (P  0.015) in the two-way ANOVA.
The sex difference in BNSTp volume previously found in rats
was also confirmed in C57BL6 mice, with BNSTp volumes
75% greater in WT males than in WT females (P  0.0005;
Table 1). There was a main effect of genotype on BNSTp volume,
with greater volumes in Bax knockout animals (P 0.0005), and
a sex-by-genotype interaction that approached, but did not reach
significance (P 0.06). Although Bax gene deletion reduced the
sex difference in BNSTp volumes, volumes remained 25%
larger in Bax males compared with Bax females (P 
0.01; Table 1).
A sex difference in cell size may explain why Bax gene deletion
did not eliminate the sex difference in BNSTp volume, despite
equal numbers of BNSTp cells in Bax males and females.
Soma size of BNSTp neurons was larger in males than in females
of both genotypes (P  0.001 for main effect of sex, and P 
0.005 for planned comparisons between males and females
within each genotype; Table 1). As has been reported for other
neural cell groups in Bax knockout mice (12), Bax gene deletion
led to a small (10%), but reliable reduction in mean cell size
in the BNSTp (P 0.0005), with no interaction between sex and
genotype on this measure.
AVPV. Total cell counts have not previously been reported for
AVPV of rats or mice, but cell density and volume estimates
(both higher in females) have led to the assumption that
females have more neurons in the AVPV than do males.
Stereological cell counts confirmed this prediction: cell num-
ber was 33% higher in the AVPV of WT females than in WT
males (P  0.005). Although the sex difference is not large, it
appears to be quite consistent as we found no overlap in cell
counts between the sexes. In keeping with the hypothesis that
Bax is required for the development of this dimorphism, a null
mutation of the Bax gene eliminated the sex difference in
AVPV neuron number (Fig. 3A). The elimination of Bax more
than doubled cell number in males (P  0.001; Figs. 3 and 4)
while increasing cell number 40% in females (P  0.03). As
a result, there was no sex difference in AVPV cell number in
Bax animals (P  0.30). In fact, in contrast to the pattern
in WT animals, Bax males had slightly (nonsignificantly)
more neurons in AVPV than did Bax females (Fig. 3A).
This latter observation likely accounts for why we did not find
a significant main effect of sex on AVPV cell number (P 0.6);
we found, however, a main effect of genotype (P 0.0005) and
a sex-by-genotype interaction (P  0.05) in the two-way
ANOVA.
Bax gene deletion also eliminated a sex difference in the length
of AVPV. Volumetric sex differences of AVPV have previously
been attributed primarily to a sex difference (female  male) in
the rostro-caudal length of the nucleus (5). In confirmation,
AVPV was longer in Bax females than in Bax males in
the present sample (P  0.01). Bax deletion increased nucleus
length (P  0.015 for main effect of genotype), but the increase
was significant only for males (P  0.05 and P  0.6 in post hoc
tests for males and females, respectively), and there was no
longer a sex difference in AVPV length among Bax animals
(P  0.3). Although the pattern of results was similar for AVPV
volumes, ANOVA indicated no significant main effects and no
interaction of sex and genotype on this measure (Table 1).
As in the BNSTp, mean cell size in AVPV was smaller in
Bax animals than in WT controls (P  0.005; Table 1).
However, there was no main effect of sex and no sex-by-genotype
interaction on AVPV cell size.
In striking contrast to our observations on nucleus length and
overall cell number, Bax deletion did not affect the number of
dopaminergic cells in AVPV. A small subset of AVPV neurons
is dopaminergic, as identified by the presence of TH, the
rate-limiting enzyme for catecholamine synthesis, and absence of
dopamine--hydroxylase, the enzyme required for conversion of
dopamine to norepinephrine (6). In confirmation of previous
reports (25, 28), the number of TH-ir neurons in AVPV was
much greater in female mice than in males (P 0.0005; Fig. 3B).
However, there was no effect of Bax gene deletion and no
sex-by-genotype interaction on TH cell number (P  0.7 in both
cases).
Discussion
The present results demonstrate that sex differences in total cell
number are absent in two forebrain regions in adult mice lacking
Bax. The most likely explanation for our findings is that Bax
deletion rescued neurons in the BNSTp and AVPV that would
otherwise die during the perinatal cell death period. If so, this
substantiates the role of cell death in sexual differentiation of the
Fig. 2. Cell number in the BNSTp of WT (Bax) and Bax knockout
(Bax) mice. Cell number in the BNSTp is greater in WT males than in
females. Deletion of the Bax gene increases cell number overall and eliminates
the sex difference. The number of animals per group is indicated at the base
of each bar. n.s., Not significant.
Table 1. Nucleus volume, nucleus length, and cell size in the
BNSTp and AVPV of WT and Bax knockout (Bax KO) mice
Cell group
Volume,
 106 3 Length, m
Soma size,
m2
BNSTp
WT male (n  6) 46.8  3.2* 445  56† 136  5*
WT female (n  6) 26.8  1.9 413  52 123  2
Bax KO male (n  7) 59.0  1.0* 467  26 120  3*
Bax KO female (n  5) 47.7  2.3 462  44 108  2
AVPV
WT male (n  4) 8.4  0.3† 233  14* 74  4 n.s.
WT female (n  6) 11.3  0.7 290  10 77  4
Bax KO male (n  6) 12.0  1.2 300  15 n.s. 58  4 n.s.
Bax KO female (n  5) 11.4  1.2 309  22 66  4
n.s., Not different from females of the same genotype.
*Significantly different from females of the same genotype.
†ANOVA not significant, post hocs not performed.
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forebrain and identifies Bax as an essential protein in that
process.
Sex differences in nuclear volumes were also reduced by Bax
gene deletion. One possible limitation of these volumetric
findings is that we examined adult, gonadally intact animals.
Circulating levels of gonadal steroid hormones in adulthood
affect neuronal size andor the volume of cell groups in several
neural regions (33–35) and could have affected volume measures
here. However, we are not aware of any reports of circulating
hormones influencing AVPV volume, and a sex difference in
BNSTp volume of guinea pigs is not altered by adult gonadec-
tomy (36). More importantly, cell counts, which form the basis
for our inferences about cell death, are not affected by this
consideration because the stereological counting techniques
used here are not influenced by the orientation, packing density,
or size of cells.
Fig. 3. Total cell number (A) and TH-ir cell number (B) in the AVPV of WT and Bax knockout mice. Counts of total cells and TH-ir cells are greater in WT females
than in WT males. Bax deletion eliminates the sex difference in total cell number, but not in TH cell number. n.s., Not significant.
Fig. 4. AVPV cell number is increased, and mean cell size is reduced by Bax gene deletion. (A and B) Low-power photomicrographs through AVPV of a Bax
male (A) and Bax male (B). (C and D) High-magnification views of the sections shown in A and B: Bax male (C) and Bax male (D). (Scale bars 
100 m for A and B; 20 m for C and D.)
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We previously reported that overexpression of the cell death
antagonist, Bcl-2, blunts sex differences in cell density in AVPV
and motoneuron number in the spinal nucleus of the bulbocav-
ernosus (25). Effects of Bcl-2 overexpression were relatively
modest, however. In addition, it is not possible in an overex-
pression study to address the physiological relevance of a given
protein. Indeed, the forced overexpression of Bcl-2 saves many
embryonic neurons from cell death, yet Bcl-2 gene deletion has
only subtle effects on developmental neuronal death in vivo (37,
38). The gene deletion approach used here allows for the
demonstration that Bcl-2 family proteins are indispensable for
the formation of sex differences in overall cell number in the
BNSTp and AVPV. Because all animals were gonadally intact in
the current study, Bax status apparently overrides endogenous
hormonal signals in determining cell number of sexually dimor-
phic forebrain nuclei. As a follow-up, we predict that perinatal
testosterone administration would reduce cell number in the
AVPV of WT females but not in their Bax knockout sisters, and
that neonatal gonadectomy would be similarly ineffective in
reducing cell number in the BNSTp of Bax males.
Cell death is a widespread, if not ubiquitous, process during
neural development (39). Our finding that a Bax gene knockout
increases overall cell number in the AVPV and BNSTp of both
sexes is consistent with observations that both males and females
exhibit pyknotic cells in these nuclei during perinatal life (10, 11),
and suggests that gonadal steroids create sex differences in
neuron number by modulating a baseline rate of cell death. If Bax
deletion prevents essentially all cell death in the BNSTp and
AVPV, as it does in other Bax-dependent neural regions (17),
then cell counts in Bax mice should reflect the number of
cells present before the onset of naturally occurring cell death.
The inference from our data (Fig. 2) is that perinatal mice
presumably start out with 30,000 neurons in the BNSTp; of
these, 35% are lost in males and 55% are lost in females. In
AVPV (Fig. 3) males may lose 52%, and females 29%, of the
5,400 neurons present in both sexes before cell death. Thus, our
results support the hypothesis that opposite patterns of cell death
are responsible for sex differences in the BNSTp and AVPV.
Although the total number of cells in AVPV was increased in
Bax mice, the subset of TH-ir neurons was not affected by
the gene knockout. Similarly, Bcl-2 overexpression had no effect
on TH cell number in AVPV in our previous study (25). Thus,
different mechanisms control the sexual differentiation of over-
all cell number and dopaminergic cell number in AVPV. It is
possible that the marked sex difference in TH cell number is not
caused by cell death. For example, testosterone (after conversion
to estradiol; ref. 28) may act on a pluripotent set of neurons in
the perinatal AVPV to inhibit differentiation of the dopaminer-
gic phenotype, leading to fewer TH-ir neurons in males. A
similar explanation has been put forward to explain sex differ-
ences in vasopressinergic neuron number in the BNSTp (26).
Our results, however, do not exclude a role for cell death in the
differentiation of dopaminergic neurons in AVPV. In fact,
exogenous estrogens reduce the number of TH-ir cells in ex-
plants of neonatal rat AVPV, and this effect can be blocked by
caspase inhibitors (E.M.W. and R.B.S., unpublished work).
Thus, the sex difference in TH-ir cell number may be caused by
a cell death program independent of Bax. In many cell types Bax
is redundant with the proapoptotic Bcl-2 family member, Bak,
and in such cases the genes for both proteins must be deleted to
prevent cell death (40, 41). Full-length Bak is reported to be
markedly reduced or absent in developing neurons (42), which
might account for the singular importance of Bax in neuronal cell
death. The pattern of results seen here could be explained if most
AVPV neurons express only Bax, but presumptive dopaminergic
neurons in AVPV express full-length Bak as well as Bax. Finally,
there are multiple apoptotic pathways (43), and it is possible that
TH-ir cell number is regulated by a cell death mechanism that
is independent of all Bcl-2 family proteins. Whatever the case
may be, our observations indicate that the control of cell number
varies not only from region to region, but also among subtypes
of neurons within a single region.
Because testosterone increases cell death in AVPV but de-
creases death in the BNSTp, the molecular control of cell
survival in these two nuclei must differ. The present results
indicate that the difference is upstream of the Bax checkpoint.
One possibility is that different hormonal metabolites modulate
cell death in the AVPV and BNSTp. Estradiol mimics effects of
testosterone on cell death in AVPV (44), but the testosterone
metabolites that regulate apoptosis in the BNSTp have not been
examined. Steroid hormone receptors may also be expressed
differentially in the two nuclei. The AVPV of adult mice
expresses predominantly ER, whereas both ER and ER are
found at high levels in the BNST (45). It is not known whether
the same pattern of results holds for perinatal mice. However,
because opposing actions have sometimes been ascribed to ER
and ER (46–48), the differential expression of steroid recep-
tors could contribute to the profound difference in response to
testosterone in the AVPV and BNSTp. Similarly, the comple-
ment of steroid receptor cofactors expressed in each nucleus
could lead to differences in hormone-induced gene expression
and cell survival in the AVPV and BNSTp (49).
Whether or not there are differences in the hormone metab-
olites, receptors, andor cofactors mediating effects of testos-
terone on cell death in the AVPV and BNSTp, the present results
suggest differential regulation of Bax activity in these two nuclei.
The subcellular distribution and death-promoting activity of Bax
is determined by interactions with other Bcl-2 family proteins
(16, 50), and there is ample evidence that gonadal steroid
hormones regulate the expression of Bax and other family
members in peripheral tissues and cancer cell lines (e.g., refs.
20–22). Moreover, in different cell types a given hormone can
have opposite effects on the expression of Bcl-2 family members
and, consequently, opposing effects on survival (51, 52). Go-
nadal steroid hormones also regulate Bcl-2 family member
expression in the nervous systems of adults (e.g., refs. 23 and 24),
including in motoneurons of the sexually dimorphic spinal
nucleus of the bulbocavernosus of adult rats (53). The results
presented here establish Bax as a protein essential for sexual
differentiation of the brain. A logical next step, therefore, is to
examine the hormonal regulation of Bcl-2 family member ex-
pression in developing sexually dimorphic forebrain regions,
with special emphasis on Bax and those proteins known to
interact with Bax.
Our observations raise the question of whether sex differences
in neuroendocrine function or behavior are affected by Bax gene
deletion. For example, the ability of estrogens to activate gona-
dotrophin releasing-hormone neurons in the forebrain and
trigger a luteinizing hormone surge is sexually differentiated in
rodents, and the AVPV is critically implicated in this response
(54, 55). Might the ‘‘feminization’’ of overall cell number in the
AVPV allow Bax males to mount a luteinizing hormone
surge? With respect to behavior, no gross changes have been
noted in Bax animals by us or other investigators (29), and
at this point, it is unlikely that more detailed behavioral obser-
vations would allow for meaningful conclusions about the func-
tional consequences of sex differences in neuron number. Neu-
rons rescued by Bax gene deletion in nonsexually dimorphic
areas often are atrophic and may not be incorporated into
functional circuits (12, 56). Consistent with these reports, we
observed a reduction in mean cell size in both the AVPV and
BNST of Bax animals. Thus, we do not know whether the
increased number of neurons in Bax mice actually alters
connectivity among sexually dimorphic brain regions. In addi-
tion, multiple brain areas are affected by the absence of Bax
(both in sexually dimorphic and monomorphic areas) and, as
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shown here, the brains of Bax mice are mosaic with respect
to sexual differentiation. For example, Bax females have a
masculine cell number in the BNSTp and feminine cell number
in AVPV. Moreover, within AVPV some cell types are affected
by Bax deletion, whereas others (i.e., TH-ir cells) are not. For
these reasons it is difficult to know what to predict regarding
behavioral changes in Baxmice or to ascribe any changes in
behavior to particular brain regions or cell types. Our findings
establish Bax mice as a powerful model for testing the role
of cell death in the development of neural sex differences and
identifying the molecular bases of hormone-regulated cell death.
Whether this model will prove equally useful in determining how
sex differences in cell number contribute to sex differences in
behavior or neuroendocrine responses will depend on our ability
to characterize the cell types rescued within sexually dimorphic
regions and establish whether rescued cells participate in func-
tional neural circuits.
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